RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1076 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $1076.
January 29, 2024 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst reaffirms an Outperform rating on Regeneron Pharmaceuticals with a price target of $1076.
The reiteration of an Outperform rating by a major analyst like RBC Capital, along with the maintenance of a high price target, is a positive signal to the market. This could lead to increased investor confidence and a potential short-term uplift in REGN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100